The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boĭko O.V.

Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza na baze Gorodskoĭ klinicheskoĭ bol'nitsy #11

Khoroshylova I.I.

OOO «Neuroclinica», Moscow, Russia

Petrov S.V.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, Elizabethan hospital, Saint-Petersburg, Russia

Mel'nikov M.V.

Kafedra obshcheĭ khirurgii Sankt-Peterburgskoĭ gosudarstvennoĭ meditsinskoĭ akademii im. I.I. Mechnikova

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab

Authors:

Boĭko O.V., Khoroshylova I.I., Petrov S.V., Mel'nikov M.V., Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2): 120‑127

DOI: 10.17116/jnevro2019119102120

Views: 16062

Downloaded: 306

Download PDF (RU)
Contact the author
Table of contents

CHANGES IN THE QUALITY OF LIFE IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH OCRELIZUMAB
CHANGES IN THE QUALITY OF LIFE IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH OCRELIZUMAB

To cite this article:

Boĭko OV, Khoroshylova II, Petrov SV, Mel'nikov MV, Boĭko AN. Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2):120‑127. (In Russ.)
https://doi.org/10.17116/jnevro2019119102120

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
Pathogenetic basis of modern approaches to the therapy of sleep diso­rders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74
Features of the clinical picture of affe­ctive diso­rders in women during the meno­pausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79
Long-term effi­cacy and safety of divo­zilimab during 2-year treatment of multiple scle­rosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96
A case of COVID-associated ence­phalopathy in a patient with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163
Opti­cal cohe­rence tomo­graphy angiography in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(2):63-70
Quality of life in patients with postoperative unilateral diaphragm rela­xation. Piro­gov Russian Journal of Surgery. 2024;(5):21-27
Asse­ssment of patient sati­sfaction during therapeutic plasmapheresis. Russian Journal of Preventive Medi­cine. 2024;(5):46-52
Life quality of universities’ students during COVID-19 pandemic. Russian Journal of Preventive Medi­cine. 2024;(5):92-96
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57

Objective. To study the quality of life (QoL) in patients with multiple sclerosis (MS) treated with ocrelizumab for at least 12 months. Material and methods. Thirty-eight patients were observed, including 13 with primary progressive MS (PPMS), 15 with highly active relapsing-remitting MS (HAMS) and 10 with secondary progressive MS (SPMS) with relapses. QoL was studied using unspecific SF-36 and MS-specific MusiQoL questionnaires. Depression and fatigue were assessed with the Beck Depression Scale (BDS) and the Modified Fatigue Impact Scale (MFIS). Results and conclusion. Basic characteristics of QoL indexes of the patients were similar to those previously reported for these MS variants. After 6 and 12 months, a significant increase in the indexes of the majority of SF-36 and MusiQoL scales was identified that shows a significant improvement in both physical and psychological domains of QoL. The significant and rapid decrease in depression severity after 6-month treatment with ocrelizumab may at least in part be associated with improvement of indexes of vitality, general health, social relations and the total QoL score.

Keywords:

multiple sclerosis
B-cells
ocrelizumab
quality of life
depression

Authors:

Boĭko O.V.

Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza na baze Gorodskoĭ klinicheskoĭ bol'nitsy #11

Khoroshylova I.I.

OOO «Neuroclinica», Moscow, Russia

Petrov S.V.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, Elizabethan hospital, Saint-Petersburg, Russia

Mel'nikov M.V.

Kafedra obshcheĭ khirurgii Sankt-Peterburgskoĭ gosudarstvennoĭ meditsinskoĭ akademii im. I.I. Mechnikova

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

List of references:

  1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622-1636. https://doi.org/10.1016/S0140-6736(18)30481-1
  2. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. https://doi.org/10.1056/NEJMoa1601277
  3. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-220. https://doi.org/10.1056/NEJMoa1606468
  4. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96-120. https://doi.org/10.1177/1352458517751049
  5. Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues: an assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmaco Economics. 2001;19:187-195.
  6. Boyko OV. Studies of the quality of life of multiple sclerosis patients. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114(10):105-113. (In Russ.)
  7. Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, Ciccarelli O. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018;14(2):75-93. https://doi.org/10.1038/nrneurol.2017.171
  8. Lee MG, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2017;11:1789-1796. https://doi.org/10.2147/PPA.S142373
  9. Fiest KM, Greenfield J, Metz LM, Patten SB, Jetté N, Marrie RA. Discriminative ability of quality of life measures in multiple sclerosis. Health Qual Life Outcomes. 2017;15(1):246-249. https://doi.org/10.1186/s12955-017-0828-0
  10. Warren S, Turpin KV, Warren KG. Health-related quality of life in MS: issues and interventions. Can J Neurol Sci. 2009;36(5):540-541. https://doi.org/10.1017/S0317167100008003
  11. Ionova TI, Novik AA, Zuchonos IA. Quality of life of patients with cancer. Vopsosy Oncologii. 1998;44(6):749-752. (In Russ.)
  12. Tatarinova MYu, Fokin IV, Boyko AN. Quality of life in multiple sclerosis and pharmaco-economic studies. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2002;102(2-2):76-80. (In Russ.)
  13. Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O’Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J; MusiQol study group. Validation of the multiple sclerosis international quality of life questionnaire. Multiple Sclerosis. 2008;14:219-230.
  14. Fernández O, Baumstarck-Barrau K, Simeoni MC, Auquier P; MusiQoL study group. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult Scler. 2011;17(10):1238-1249. https://doi.org/10.1177/1352458511407951
  15. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. https://doi.org/10.1016/S1474-4422(17)30470-2
  16. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
  17. Lebedeva AV, Shchukin IA, Soldatov MA, Boyko OV, Petrov SV, Khozova AA, Ismailov AM, Shikhkerimov RK, Boyko AN. Asthenia, emotional disorders and quality of life of patients with multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114(10-2):99-104. (In Russ.)
  18. Vlasov YaV, Churakov MV, Kurapov MA, Gromova TN, Popova EV, Boyko OV, Spirin NN, Sivertseva SA, Belskaya GN, Malkova NA, Habirov FA, Haybullin TI, Kotov SV, Greshnova IV, Ivashinenkova EI, Bakalova MA, Boyko AN. Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(8-2):40-46. (In Russ.) https://doi.org/10.17116/jnevro201811808240
  19. Malkova NA, Rjabukhina OV, Ionova TI, Kishtovich AV. Study of the quality of life of multiple sclerosis patients in Novosibirsk. Nevrologicheskyi Zurnal. 2005;10(4):17-20. (In Russ.)
  20. Malkova NA, Ryabukhina OV, Babenko LA. Health depended quality of life of patients with multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova. 2005, 105, 12: 31-37. (In Russ)
  21. Boyko OV, Tatarinova MYu, Popova EV, Guseva MR, Boyko AN, Gusev EI. The improvement of quality of life of patients with multiple sclerosis over 15-year period. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(8-2):23-28. (In Russ.) https://doi.org/10.17116/jnevro201811808223
  22. Boyko OV, Boyko AN, Guseva MR. Changes in quality of life in multiple sclerosis patients, receiving natalizumab. Nevrologicheskyi Zurnal. 2018;1:42-46. (In Russ.) https://doi.org/10.18821/1560-9545-2018-23-1
  23. Planche V, Moisset X, Morello R, Dumont E, Gibelin M, Charré-Morin J, Saubusse A, Mondou A, Reuter F, Defer G, Pelletier J, Brochet B, Clavelou P. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study. J Neurol Sci. 2017;382:148-154. https://doi.org/10.1016/j.jns.2017.10.008
  24. Foley JF, Nair KV, Vollmer T, Stephenson JJ, Niecko T, Agarwal SS, Watson C. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Prefer Adherence. 2017;11:1035-1048. https://doi.org/10.2147/PPA.S134865
  25. Boster A, Arroyo R, Boyko AN, Eichau S, Graves D, Hillstrand MM, Ionete C, Limmroth V, Navas C, Pozzilli C, Ravenscroft J, Sousa1 L, Tintorè M, Chung L, Daizadeh N, Rodriguez CE, Morawski J, Rog D. Improvements in multiple domains of quality of life with alemtuzumab as assessed by the functional assessment of multiple sclerosis questionnaire over 6 years regardless of presence of thyroid adverse events. Multiple Sclerosis. 2018;24(suppl 2):503-511. https://doi.org/10.1177/1352458518798579
  26. Boyko AN, Evdoshenko EP, Vorob’eva OV, You X, Pukaite V. A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(8-2):25-35. (In Russ.) https://doi.org/10.17116/jnevro20151158225-35
  27. Ancau M, Berthele A, Hemmer B. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opin Biol Ther. 2019;24:1-15. https://doi.org/10.1080/14712598.2019.1611778

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.